Abstract
The aim of treatment in patients at high risk for fractures is to reduce the risk of a first or a subsequent fracture. Vertebral and nonvertebral fracture prevention (including hip) using currently available bisphosphonates, denosumab and teriparatide is effective with a reasonable safety profile in severe osteoporosis.
Initiation of and adherence to fracture prevention drugs are still low. New potential developments of promising new drugs with new mechanisms of action include an antiresorptive odanacatib, a selective inhibitor of cathepsin K, and osteoanabolic drugs, monoclonal antibodies against sclerostin